Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: Systematic review and economic evaluation

Health Technology Assessment

Volumn 19, Issue 51, 2015, Pages 1-248

  Royle, Pamela ^a   Mistry, Hema ^a   Auguste, Peter ^a   Shyangdan, Deepson ^a   Freeman, Karoline ^a   Lois, Noemi ^b   Waugh, Norman ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGON; BEVACIZUMAB; FENOFIBRATE; GLUCOSE; PLACEBO; RANIBIZUMAB; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; XENON; VASCULOTROPIN A;

ADJUVANT THERAPY; ADVERSE OUTCOME; ARGON LASER; ARTICLE; BLOOD PRESSURE; CLINICAL PROTOCOL; COLOR VISION; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIODE LASER; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; ECONOMIC EVALUATION; GLUCOSE BLOOD LEVEL; HOME CARE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; LOW LEVEL LASER THERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PATIENT ASSESSMENT; PREVALENCE; PROLIFERATIVE DIABETIC RETINOPATHY; REMISSION; SYSTEMATIC REVIEW; VISUAL FIELD; VISUAL IMPAIRMENT; VITRECTOMY; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; PROCEDURES;

COST-BENEFIT ANALYSIS; DIABETIC RETINOPATHY; HUMANS; LASER COAGULATION; MODELS, ECONOMIC; STEROIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938064746     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta19510     Document Type: Article

References (202)

1. Arun CS, Al-Bermani A, Stannard K, Taylor R. Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age population. Diabet Med 2009;26:489-92. http://dx.doi.org/10.1111/j.1464-5491.2009.02718.x
2. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32:2307-13. http://dx.doi.org/10.2337/dc09-0615
3. LeCaire TJ, Palta M, Klein R, Klein BE, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2013;36:631-7. http://dx.doi.org/10.2337/dc12-0863
4. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in Type 1 diabetes in a systematic screening programme. Diabet Med 2003;20:758-65. http://dx.doi.org/10.1046/j.1464-5491.2003.01035.x
5. The Royal College of Ophthalmologists. Guidelines for Diabetic Retinopathy. 2012. URL: www.rcophth.ac.uk/page.asp?section=451§ionTitle=Clinical+Guidelines (accessed 24 September 2013).
6. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98:823-33. http://dx.doi.org/10.1016/S0161-6420(13)38014-2
7. NHS Screening Programmes. NHS Diabetic Eye Screening Programme; 2013. URL: http://diabeticeye. screening.nhs.uk/ (accessed 17 March 2014).
8. NHS Scotland. Scottish Diabetic Retinopathy Screening Collaborative 2013. URL: www.ndrs.scot. nhs.uk/ (accessed 17 March 2014).
9. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991;98:766-85. http://dx.doi.org/10.1016/ S0161-6420(13)38011-7
10. Diabetic Retinopathy Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology 1981;88:583-600.
11. Lovestam-Adrian M, Agardh CD, Torffvit O, Agardh E. Type 1 diabetes patients with severe non-proliferative retinopathy may benefit from panretinal photocoagulation. Acta Ophthalmol Scand 2003;81:221-5. http://dx.doi.org/10.1034/j.1600-0420.2003.00050.x
12. Stenkula S. Photocoagulation in diabetic retinopathy. A multicentre study in Sweden. Acta Ophthalmol Scand Suppl 1984;162:1-100.
13. Neubauer AS, Ulbig MW. Laser treatment in diabetic retinopathy. Ophthalmologica 2007;221:95-102. http://dx.doi.org/10.1159/000098254
14. Clarkson D. Multi-spot Laser Photocoagulation; 2012. URL: www.opticianonline.net/assets/ getAsset.aspx?ItemID=6214 (accessed 23 March 2014).
15. Sivaprasad S, Dorin G. Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema. Expert Rev Med Devices 2012;9:189-97. http://dx.doi.org/ 10.1586/erd.12.1
16. Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol 2010;55:516-30. http://dx.doi.org/10.1016/ j.survophthal.2010.02.005
17. Japanese Society of Ophthalmic Diabetology: Subcommittee on the Study of Diabetic Retinopathy Treatment, Sato Y, Kojimahara N, Kitano S, Kato S, Ando N, et al. Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Jpn J Ophthalmol 2012;56:52-9. http://dx.doi.org/10.1007/s10384-011-0095-2
18. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes: SIGN 116; 2010. URL: www.sign.ac.uk/pdf/sign116.pdf (accessed 24 September 2013).
19. National Institute for Health and Clinical Excellence (NICE). CG15 Type 1 Diabetes in Children, Young People and Adults. NICE Guideline 2012. URL: www.nice.org.uk/guidance/CG15/ NICEGuidance (accessed 17 March 2014).
20. National Institute for Health and Clinical Excellence (NICE). CG66 Type 2 Diabetes (partially updated by CG87) 2008. URL: http://guidance.nice.org.uk/CG66 (accessed 17 March 2014).
21. Diabetic Retinopathy Clinical Research Network (DRCRnet). Protocol: Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy; 2011. URL: http://drcrnet.jaeb.org/Studies.aspx?RecID=201 (accessed 26 February 2014).
22. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. http://dx.doi.org/10.1056/NEJM199412013312203
23. Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open 2013;3:e002269. http://dx.doi.org/ 10.1136/bmjopen-2012-002269
24. CATT Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98. http://dx.doi.org/10.1016/j.ophtha.2012.03.053
25. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97. http://dx.doi.org/10.1016/S0140-6736(07)61607-9
26. ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-44. http://dx.doi.org/10.1056/NEJMoa1001288
27. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. http://dx.doi.org/10.1016/S0140-6736(04)16895-5
28. Chen Y, Lu B, Zhang Q, Ma J. Therapeutic effect of fenofibrate eyedrops on diabetic retinopathy: poster 453/D1130; ARVO Meeting, Fort Lauderdale, FL, USA, 6 May 2012.
29. McCall B. World First Approval for Fenofibrate in Diabetic Retinopathy; 2013. URL: www. medscape.com/viewarticle/815213 (accessed 17 March 2014).
30. Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, Greve M, et al. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. Can J Ophthalmol 2012;47:S1-30,s1-54. http://dx.doi.org/10.1016/ j.jcjo.2011.12.025
31. American Academy of Ophthalmology. Diabetic Retinopathy PPP-updated October 2012; 2008. URL: http://one.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-september- 2008-4th-print (accessed 29 September 2013).
32. Australian Government: National Health and Medical Research Council (NHMRC), Mitchell P, Foran S. Guidelines for the Management of Diabetic Retinopathy; 2008. URL: www.nhmrc.gov. au/_files_nhmrc/publications/attachments/di15.pdf (accessed 17 March 2014).
33. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902-16. http://dx.doi.org/10.1001/jama.298.8.902
34. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed) 2011;343:d5928. http://dx.doi.org/10.1136/bmj.d5928
35. Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-96. http://dx.doi.org/10.1016/0002-9394(76)90292-0
36. Diabetic Retinopathy Study Research Group. Diabetic retinopathy study, report number 6: design, methods, and baseline results. Invest Ophthalmol Vis Sci 1981;21:149-209.
37. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978;85:82-106. http://dx.doi.org/10.1016/S0161-6420(78)35693-1
38. Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. Int Ophthalmol Clin 1987;27:239-53. http://dx.doi.org/10.1097/00004397-198702740-00004
39. Ferris FL III, Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study patients; Diabetic Retinopathy Study Report Number 12. Ophthalmology 1987;94:754-60. http://dx.doi.org/ 10.1016/S0161-6420(87)33526-2
40. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics; ETDRS report number 7. Ophthalmology 1991;98:741-56. http://dx.doi.org/10.1016/S0161-6420(13)38009-9
41. Fong DS, Ferris FL, Davis MD, Chew EY. Causes of severe visual loss in the early treatment diabetic retinopathy study; ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group. Am J Ophthalmol 1999;127:137-41. http://dx.doi.org/10.1016/S0002-9394(98) 00309-2
42. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc 1996;94:505-37.
43. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial; Diabetic Retinopathy Vitrectomy Study Report 2. Arch Ophthalmol 1985;103:1644-52. http://dx.doi.org/10.1001/ archopht.1985.01050110038020
44. Flynn HW, Jr, Chew EY, Simons BD, Barton FB, Remaley NA, Ferris FL III. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1992;99:1351-7. http://dx.doi.org/ 10.1016/S0161-6420(92)31779-8
45. Chew EY, Benson WE, Remaley NA, Lindley AA, Burton TC, Csaky K, et al. Results after lens extraction in patients with diabetic retinopathy: early treatment diabetic retinopathy study report number 25. Arch Ophthalmol 1999;117:1600-6. http://dx.doi.org/10.1001/archopht.117.12.1600
46. Chantelau E, Kohner EM. Why some cases of retinopathy worsen when diabetic control improves. BMJ (Clin Res Ed) 1997;315:1105-6. http://dx.doi.org/10.1136/bmj.315.7116.1105
47. Pautler SE. Treatment of proliferative diabetic retinopathy. In Browning DJ, editor. Diabetic Retinopathy: Evidence Based Management. New York: Springer; 2010. pp. 227-304. http://dx.doi.org/10.1007/978-0-387-85900-2_9
48. Williamson TH, George N, Flanagan DW, Norris V, Blamires T. Driving standard visual fields in diabetic patients after panretinal laser photocoagulation. In Gale AG, editor. Vision in Vehicles III. North Holland: 1991; pp. 265-72.
49. Shimura M, Yasuda K, Nakazawa T, Tamai M. Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Am J Ophthalmol 2005;140:8-15. http://dx.doi.org/10.1016/j.ajo.2005.02.029
50. Browning DJ. Visual dysfunction after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Am J Ophthalmol 2005;140:127-8. http://dx.doi.org/10.1016/ j.ajo.2005.03.025
51. Browning DJ, McOwen MD, Bowen RM Jr, O'Marah TL. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology 2004;111:712-15. http://dx.doi.org/10.1016/j.ophtha.2003.06.028
52. Massin P, Girach A, Erginay A, Gaudric A. Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. Acta Ophthalmol Scand 2006;84:466-74. http://dx.doi.org/10.1111/j.1600-0420.2006.00694.x
53. Browning DJ, Fraser CM, Clark S. The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema. Ophthalmology 2008;115:533-9.e2. http://dx.doi.org/10.1016/j.ophtha.2007.06.042
54. Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, et al. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007;125:469-80. http://dx.doi.org/10.1001/archopht.125.4.469
55. Tewari HK, Ravindranath HM, Kumar A, Verma L. Diode laser scatter photocoagulation in diabetic retinopathy. Ann Ophthalmol 2000;32:110-12. http://dx.doi.org/10.1007/s12009-000-0027-0
56. Bandello F, Polito A, Del Borrello M, Zemella N, Isola M. 'Light' versus 'classic' laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 2005;89:864-70. http://dx.doi.org/ 10.1136/bjo.2004.051060
57. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013;131:1033-40. http://dx.doi.org/10.1001/ jamaophthalmol.2013.4154
58. Brown CD. A comparative study of panretinal photocoagulation and vitrectomy for advanced diabetic retinopathy. Mil Med 2003;168:553-5.
59. Cardillo JA, Lavinsky D, Melo LAS, Dare A, Castro L, Costa RA, et al. Comparison of the modified early treatment diabetic retinopathy study and normal or high density subthreshold infrared micro pulsed photocoagulation for diabetic macular edema; 2008. URL: www.iovs.org: ARVO e-abstract no. 1566.
60. Chappelow AV, Tan K, Waheed NK, Kaiser PK. Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser. Am J Ophthalmol 2012;153:137-42.e2. http://dx.doi.org/10.1016/j.ajo.2011.05.035
61. Cho WB, Oh SB, Moon JW, Kim HC. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina 2009;29:516-22. http://dx.doi. org/10.1097/IAE.0b013e31819a5fc2
62. Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, et al. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 2009;127:132-40. http://dx.doi.org/10.1001/archophthalmol.2008.565
63. Gurelik G, Coney JM, Zakov ZN. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging 2004;35:94-102.
64. Lee CM, Olk RJ, Akduman L. Combined modified grid and panretinal photocoagulation for diffuse diabetic macular edema and proliferative diabetic retinopathy. Ophthalmic Surg Las 2000;31:292-300.
65. Lee SB, Yun YJ, Kim SH, Kim JY. Changes in macular thickness after panretinal photocoagulation in patients with severe diabetic retinopathy and no macular edema. Retina 2010;30:756-60. http://dx.doi.org/10.1097/IAE.0b013e3181c701e0
66. Luttrull JK, Musch DC, Spink CA. Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy. Eye 2008;22:607-12. http://dx.doi.org/10.1038/sj.eye.6702725
67. Mason JO, Yunker JJ, Vail R, McGwin G Jr., Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina 2008;28:1319-24. http://dx.doi.org/10.1097/IAE.0b013e31818356fb
68. Muqit MMK, Marcellino GR, Henson DB, Young LB, Patton N, Charles SJ, et al. Optos-guided pattern scan laser (PASCAL)-targeted retinal photocoagulation in proliferative diabetic retinopathy. Acta Ophthalmol 2013;91:251-8. http://dx.doi.org/10.1111/j.1755-3768.2011. 02307.x
69. Summanen P. Scatter photocoagulation: pros and cons with old and new laser equipments. Acta Ophthalmol 2012;90:36.
70. Venkatesh P, Ramanjulu R, Azad R, Vohra R, Garg S. Subthreshold micropulse diode laser and double frequency neodymium: YAG laser in treatment of diabetic macular edema: a prospective, randomized study using multifocal electroretinography. Photomed Laser Surg 2011;29:727-33. http://dx.doi.org/10.1089/pho.2010.2830
71. Vujosevic S, Bottega E, Casciano M, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010;30:908-16. http://dx.doi.org/10.1097/IAE.0b013e3181c96986
72. Zucchiatti I, Veritti D, Lanzetta P, Bandello F. Efficacy and safety of PASCAL photocoagulator in the treatment of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2009;50:194-5.
73. Bandello F, Brancato R, Menchini U, Virgili G, Lanzetta P, Ferrari E, et al. Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy. Semin Ophthalmol 2001;16:12-18. http://dx.doi.org/10.1076/soph.16.1.12.4223
74. Muqit MM, Marcellino GR, Gray JC, McLauchlan R, Henson DB, Young LB, et al. Pain responses of Pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2. Br J Ophthalmol 2010;94:1493-8. http://dx.doi.org/10.1136/ bjo.2009.176677
75. Muqit MM, Marcellino GR, Henson DB, Young LB, Patton N, Charles SJ, et al. Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: The Manchester Pascal Study. Arch Ophthalmol 2010;128:525-33. http://dx.doi.org/ 10.1001/archophthalmol.2010.60
76. Muqit MM, Marcellino GR, Henson DB, Young LB, Turner GS, Stanga PE. Pascal panretinal laser ablation and regression analysis in proliferative diabetic retinopathy: Manchester Pascal Study Report 4. Eye 2011;25:1447-56. http://dx.doi.org/10.1038/eye.2011.188
77. Muqit MMK, Young LB, McKenzie R, John B, Marcellino GR, Henson DB, et al. Pilot randomised clinical trial of Pascal TargETEd Retinal versus variable fluence PANretinal 20 ms laser in diabetic retinopathy: PETER PAN study. Br J Ophthalmol 2013;97:220-7. http://dx.doi.org/10.1136/ bjophthalmol-2012-302189
78. Muraly P, Limbad P, Srinivasan K, Ramasamy K. Single session of Pascal versus multiple sessions of conventional laser for panretinal photocoagulation in proliferative diabetic retinopathy: a comparative study. Retina 2011;31:1359-65. http://dx.doi.org/10.1097/IAE.0b013e318203c140
79. Al-Hussainy S, Dodson PM, Gibson JM. Pain response and follow-up of patients undergoing panretinal laser photocoagulation with reduced exposure times. Eye 2008;22:96-9. http://dx.doi. org/10.1038/sj.eye.6703026
80. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110:2386-94. http://dx.doi.org/10.1016/ j.ophtha.2003.05.008
81. Mirshahi A, Lashay A, Roozbahani M, Fard MA, Molaie S, Mireshghi M, et al. Pain score of patients undergoing single spot, short pulse laser versus conventional laser for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2013;251:1103-7. http://dx.doi.org/10.1007/ s00417-012-2167-5
82. Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina 2010;30:452-8. http://dx.doi.org/10.1097/IAE.0b013e3181c70127
83. Salman AG. Pascal laser versus conventional laser for treatment of diabetic retinopathy. Saudi J Ophthalmol 2011;25:175-9. http://dx.doi.org/10.1016/j.sjopt.2011.01.006
84. Suto C, Hori S, Kato S. Management of type 2 diabetics requiring panretinal photocoagulation and cataract surgery. J Cataract Refract Surg 2008;34:1001-6. http://dx.doi.org/10.1016/ j.jcrs.2008.02.019
85. Shimizu Y, Kojima K. Clinical analysis of preproliferative diabetic retinopathy prognosis of photocoagulation. Folia Ophthalmol Jpn 1989;40:1635-42.
86. Jojo V, Mohamed M. Re: Single session of Pascal versus multiple sessions of conventional laser for panretinal photocoagulation in proliferative diabetic retinopathy: a comparative study. Retina 2012;32:1697-8; author reply 8-9. http://dx.doi.org/10.1097/IAE.0b013e3182695b03
87. Muraly M, Limbad P, Srinivasan K, Amasamy K. Re: Single session of Pascal versus multiple sessions of conventional laser for panretinal photocoagulation in proliferative diabetic retinopathy: a comparative study. Retina 2012;32:1698-9. http://dx.doi.org/10.1097/IAE.0b013e3182695be4
88. Bandello F, Brancato R, Trabucchi G, Lattanzio R, Malegori A. Diode versus argon-green laser panretinal photocoagulation in proliferative diabetic retinopathy: a randomized study in 44 eyes with a long follow-up time. Graefes Arch Clin Exp Ophthalmol 1993;231:491-4. http://dx.doi.org/ 10.1007/BF00921112
89. Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009;93:1341-4. http://dx.doi.org/10.1136/bjo.2008.146712
90. Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004;88:1173-9. http://dx.doi.org/10.1136/ bjo.2003.040949
91. Lavinsky D, Cardillo JA, Melo LA, Jr, Dare A, Farah ME, Belfort R Jr, Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 2011;52:4314-23. http://dx.doi.org/10.1167/iovs. 10-6828
92. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a 'trial effect'. J Clin Epidemiol 2001;54:217-24. http://dx.doi.org/10.1016/ S0895-4356(00)00305-X
93. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2008:3;MR000009. http://dx.doi.org/10.1002/ 14651858.mr000009.pub4
94. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007;27:816-24. http://dx.doi.org/10.1097/IAE.0b013e318042d32c
95. Diabetic Retinopathy Clinical Research Network, Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-36. http://dx.doi.org/10.1016/j.ophtha.2006.06.052
96. Du B, Zhang H, Chan HHL, Wang JT, Ho PWC, Xu YS. Retinal function and morphology of severe non-proliferative diabetic retinopathy before and after retinal photocoagulation. Clin Exp Optom 2011;94:284-90. http://dx.doi.org/10.1111/j.1444-0938.2011.00585.x
97. Maeshima K, Utsugi-Sutoh N, Otani T, Kishi S. Progressive enlargement of scattered photocoagulation scars in diabetic retinopathy. Retina 2004;24:507-11. http://dx.doi.org/10.1097/ 00006982-200408000-00002
98. Raman R, Ananth V, Pal SS, Gupta A. Internal ophthalmoplegia after retinal laser photocoagulation. Cutan Ocul Toxicol 2010;29:203-8. http://dx.doi.org/10.3109/15569527. 2010.489336
99. Shimura M, Yasuda K, Nakazawa T, Abe T, Shiono T, Iida T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:1617-24. http://dx.doi.org/10.1007/ s00417-009-1147-x
100. Wang Y, Muqit MM, Stanga PE, Young LB, Henson DB. Spatial changes of central field loss in diabetic retinopathy after laser. Optom Vis Sci 2014;91:111-20. http://dx.doi.org/10.1097/ OPX.0000000000000103
101. Kaiser RS, Maguire MG, Grunwald JE, Lieb D, Jani B, Brucker AJ, et al. One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol 2000;129:178-85. http://dx.doi.org/10.1016/S0002-9394(99)00322-0
102. Kovacic Z, Ivanisevic M, Bojic L, Hrgovic Z, Lesin M, Kurelovic D. Comparing two techniques of panretinal photocoagulation on visual acuity on patients with proliferative diabetic retinopathy. Med Arh 2012;66:321-3. http://dx.doi.org/10.5455/medarh.2012.66.321-323
103. Tinley CG, Gray RH. Routine, single session, indirect laser for proliferative diabetic retinopathy. Eye 2009;23:1819-23. http://dx.doi.org/10.1038/eye.2008.394
104. Velez-Montoya R, Guerrero-Naranjo JL, Gonzalez-Mijares CC, Fromow-Guerra J, Marcellino GR, Quiroz-Mercado H, et al. Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive cases. Br J Ophthalmol 2010;94:720-4. http://dx.doi.org/ 10.1136/bjo.2009.164996
105. Natesh S, Ranganath A, Harsha K, Yadav NK, Bhujang BS. Choroidal detachment after PASCAL photocoagulation. Can J Ophthalmol 2011;46:91. http://dx.doi.org/10.3129/i10-108
106. Kapoor B, Peh KK, Raman SV. An unusual case of acute angle closure glaucoma following argon laser pan retinal photocoagulation. BMJ Case Rep 2010. http://dx.doi.org/10.1136/ bcr.12.2009.2511
107. Richardson C, Waterman H. Pain relief during panretinal photocoagulation for diabetic retinopathy: a national survey. Eye 2009;23:2233-7. http://dx.doi.org/10.1038/eye.2008.421
108. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. II. Proliferative retinopathy. Eye 1998;12:77-84. http://dx.doi.org/10.1038/eye.1998.14
109. Stanga PE, Muqit MM. Re: Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina 2010;30:1749-50; author reply 50-1.
110. Bressler NM, Beck RW, Ferris LF. Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med 2011;365:1520-6. http://dx.doi.org/10.1056/NEJMct0908432
111. Yang CS, Cheng CY, Lee FL, Hsu WM, Liu JH. Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. Acta Ophthalmol Scand 2001;79:266-70. http://dx.doi.org/10.1034/j.1600-0420. 2001.790311.x
112. Mackie SW, Webb LA, Hutchison BM, Hammer HM, Barrie T, Walsh G. How much blame can be placed on laser photocoagulation for failure to attain driving standards? Eye 1995;9:517-25. http://dx.doi.org/10.1038/eye.1995.118
113. Vernon SA, Bhagey J, Boraik M, El-Defrawy H. Long-term review of driving potential following bilateral panretinal photocoagulation for proliferative diabetic retinopathy. Diabet Med 2009;26:97-9. http://dx.doi.org/10.1111/j.1464-5491.2008.02623.x
114. Hulbert MFG, Vernon SA. Passing the DLVC field regulations following bilateral pan-retinal photocoagulation in diabetics. Eye 1996;6:456-60. http://dx.doi.org/10.1038/eye.1992.96
115. Davies N. Altering the pattern of panretinal photocoagulation: could the visual field for driving be preserved? Eye 1999;13:531-6. http://dx.doi.org/10.1038/eye.1999.132
116. Quinn MJ. Can altering the pattern of laser photocoagulation for proliferative diabetic retinopathy help retain visual fields for driving? Eye 1999;13:495-6. http://dx.doi.org/10.1038/eye.1999.129
117. Whittington Health NHS. Preparing for Laser Treatment for Diabetic Retinopathy and Maculopathy; 2013. URL: www.whittington.nhs.uk/document.ashx?id = 818 (accessed 25 March 2014).
118. Diabetes UK. Driving and Diabetes; 2009. URL: www.diabetes.org.uk/upload/How%20we% 20help/catalogue/DrivingandDiabetes_Final_ToUpload.pdf (accessed 25 March 2014).
119. Cho WB, Moon JW, Kim HC. Intravitreal triamcinolone and bevacizumab as adjunctive treatments to panretinal photocoagulation in diabetic retinopathy. Br J Ophthalmol 2010;94:858-63. http://dx.doi.org/10.1136/bjo.2009.168997
120. Diabetic Retinopathy Clinical Research Network (DRCRnet). Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009-27. http://dx.doi.org/10.1097/IAE.0b013e318217d739
121. Ernst BJ, Garcia-Aguirre G, Oliver SC, Olson JL, Mandava N, Quiroz-Mercado H. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naive proliferative and severe nonproliferative diabetic retinopathy. Acta Opthalmol 2012;90:e573-4. http://dx.doi.org/10.1111/ j.1755-3768.2011.02364.x
122. Filho JAR, Messias A, Almeida FPP, Ribeiro JAS, Costa RA, Scott IU, et al. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol 2011;89:e567-72. http://dx.doi.org/10.1111/j.1755-3768.2011. 02184.x
123. Lucena CR, Ramos Filho JA, Messias AM, da Silva JA, de Almeida FP, Scott IU, et al. Panretinal photocoagulation versus intravitreal injection retreatment pain in high-risk proliferative diabetic retinopathy. Arq Bras Oftalmol 2013;76:18-20. http://dx.doi.org/10.1590/ S0004-27492013000100006
124. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumabaugmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol 2008;18:263-9.
125. Preti RC, Vasquez Ramirez LM, Ribeiro Monteiro ML, Pelayes DE, Takahashi WY. Structural and functional assessment of macula in patients with high-risk proliferative diabetic retinopathy submitted to Panretinal photocoagulation and associated intravitreal bevacizumab injections: a comparative, randomised, controlled trial. Ophthalmologica 2013;230:1-8. http://dx.doi.org/ 10.1159/000348605
126. Tonello M, Costa RA, Almeida FP, Barbosa JC, Scott IU, Jorge R. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol 2008;86:385-9. http://dx.doi.org/10.1111/j.1600-0420.2007.01056.x
127. Maia OO Jr, Takahashi BS, Costa RA, Scott IU, Takahashi WY. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol 2009;147:291-7.e2. http://dx.doi.org/10.1016/ j.ajo.2008.08.024
128. Mirshahi A, Shenazandi H, Lashay A, Faghihi H, Alimahmoudi A, Dianat S. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema. Retina 2010;30:254-9. http://dx.doi.org/ 10.1097/IAE.0b013e3181b4f125
129. Shimura M, Yasuda K, Shiono T. Posterior sub-Tenon's capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision. Ophthalmology 2006;113:381-7. http://dx.doi.org/10.1016/ j.ophtha.2005.10.035
130. Unoki N, Nishijima K, Kita M, Suzuma K, Watanabe D, Oh H, et al. Randomised controlled trial of posterior sub-Tenon triamcinolone as adjunct to panretinal photocoagulation for treatment of diabetic retinopathy. Br J Ophthalmol 2009;93:765-70. http://dx.doi.org/10.1136/ bjo.2008.152041
131. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research; Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health 2013;16:e1-5. http://dx.doi.org/10.1016/j.jval.2013.02.010
132. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36). http://dx.doi.org/10.3310/hta8360
133. Fenwick EK, Lamoureux EL. Effect of pan-retinal photocoagulation treatment on vision-related quality of life of patients with proliferative diabetic retinopathy. Retina 2013;33:1479. http://dx.doi.org/10.1097/IAE.0b013e3182928b33
134. Scanlon PH, Martin ML, Bailey C, Johnson E, Hykin P, Keightley S. Reported symptoms and quality-of-life impacts in patients having laser treatment for sight-threatening diabetic retinopathy. Diabet Med 2006;23:60-6. http://dx.doi.org/10.1111/j.1464-5491.2005.01736.x
135. Tsilimbaris MK, Kontadakis GA, Tsika C, Papageorgiou D, Charoniti M. Effect of panretinal photocoagulation treatment on vision-related quality of life of patients with proliferative diabetic retinopathy. Retina 2013;33:756-61. http://dx.doi.org/10.1097/IAE.0b013e31826b0c06
136. Wirostko B, Beusterien K, Grinspan J, Ciulla T, Gonder J, Barsdorf A, et al. Patient preferences in the treatment of diabetic retinopathy. Patient Prefer Adherence 2011;5:229-37. http://dx.doi.org/ 10.2147/PPA.S11972
137. Mozaffarieh M, Benesch T, Sacu S, Krepler K, Biowski R, Wedrich A. Photocoagulation for diabetic retinopathy: determinants of patient satisfaction and the patient-provider relationship. Acta Ophthalmol Scand 2005;83:316-21. http://dx.doi.org/10.1111/j.1600-0420.2005.00455.x
138. Trento M, Tomelini M, Lattanzio R, Brancato R, Coggiola A, Benecchi R, et al. Perception of, and anxiety levels induced by, laser treatment in patients with sight-threatening diabetic retinopathy. A multicentre study. Diabet Med 2006;23:1106-9. http://dx.doi.org/10.1111/j.1464-5491.2006. 01957.x
139. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:1050-8. http://dx.doi.org/10.1001/archopht.119.7.1050
140. Browne C, Brazier J, Carlton J, Alavi Y, Jofre-Bonet M. Estimating quality-adjusted life years from patient-reported visual functioning. Eye 2012;26:1295-301. http://dx.doi.org/10.1038/eye.2012.137
141. Payakachat N, Summers KH, Pleil AM, Murawski MM, Thomas J III, Jennings K, et al. Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration. Qual Life Res 2009;18:801-13. http://dx.doi.org/10.1007/s11136-009-9499-6
142. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ (Clin Res Ed) 2000;320:1530-3. http://dx.doi.org/10.1136/bmj.320.7248.1530
143. Diabetes in Scotland. Scottish Diabetes Survey; 2012. URL: www.diabetesinscotland.org.uk/ Publications.aspx?catId = 3 (accessed 21 March 2014).
144. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes: the Linkoping Diabetes Complications Study. Diabetologia 2004;47:1266-72. http://dx.doi.org/10.1007/ s00125-004-1431-6
145. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. Ophthalmology 1995;102:647-61. http://dx.doi.org/10.1016/S0161-6420(95)30973-6
146. The Health and Social Care Information Centre (HSCIC), Diabetes UK. National Diabetes Audit 2011-2012 Report 1: Care Processes and Treatment Targets. URL: www.hqip.org.uk/assets/ NCAPOP-Library/NCAPOP-2013-14/NDA-2011-2012-CareProcessesTreatmentTargets.pdf (accessed 21 March 2014).
147. DCCT/EDIC Study Research Group, Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53. http://dx.doi.org/10.1056/NEJMoa052187
148. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-15. http://dx.doi.org/10.1016/ S0161-6420(98)91020-X
149. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-63. http://dx.doi.org/10.1007/s001250051594
150. Harris Nwanyanwu K, Talwar N, Gardner TW, Wrobel JS, Herman WH, Stein JD. Predicting development of proliferative diabetic retinopathy. Diabetes Care 2013;36:1562-8. http://dx.doi.org/10.2337/dc12-0790
151. Cikamatana L, Mitchell P, Rochtchina E, Foran S, Wang JJ. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye 2007;21:465-71. http://dx.doi.org/10.1038/sj.eye.6702771
152. Jones CD, Greenwood RH, Misra A, Bachmann MO. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes Care 2012;35:592-6. http://dx.doi.org/10.2337/dc11-0943
153. McCarty DJ, Fu CL, Harper CA, Taylor HR, McCarty CA. Five-year incidence of diabetic retinopathy in the Melbourne Visual Impairment Project. Clin Experiment Ophthalmol 2003;31:397-402. http://dx.doi.org/10.1046/j.1442-9071.2003.00685.x
154. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report 18. Invest Ophthalmol Vis Sci 1998;39:233-52.
155. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008;115:1859-68. http://dx.doi.org/10.1016/j.ophtha.2008.08.023
156. Scanlon PH, Stratton IM, Histed M, Chave SJ, Aldington SJ. The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. Acta Ophthalmol 2013;91:e335-9. http://dx.doi.org/10.1111/aos.12074
157. Ting HYJ, Martin DK, Haas M. A Markov Model of Diabetic Retinopathy Progression for the Economic Evaluation of a novel DR prognostic device: CHERE Working Paper 2007/14; 2007. URL: www.chere.uts.edu.au/pdf/wp2007_14.pdf (accessed 18 March 2014).
158. Rodgers M, Hodges R, Hawkins J, Hollingworth W, Duffy S, McKibbin M, et al. Colour vision testing for diabetic retinopathy: a systematic review of diagnostic accuracy and economic evaluation. Health Technol Assess 2009;13(60). http://dx.doi.org/10.3310/hta13600
159. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27-40. http://dx.doi.org/10.1185/030079904X2006
160. Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology 2013;120:566-73. http://dx.doi.org/10.1016/j.ophtha.2012.09.002
161. Brown MM, Brown GC, Sharma S, Shah G. Utility values and diabetic retinopathy. Am J Ophthalmol 1999;128:324-30. http://dx.doi.org/10.1016/S0002-9394(99)00146-4
162. Fong DS, Sharza M, Chen W, Paschal JF, Ariyasu RG, Lee PP. Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am J Ophthalmol 2002;133:236-41. http://dx.doi.org/10.1016/S0002-9394(01)01364-2
163. Smith DH, Johnson ES, Russell A, Hazlehurst B, Muraki C, Nichols GA, et al. Lower visual acuity predicts worse utility values among patients with type 2 diabetes. Qual Life Res 2008;17:1277-84. http://dx.doi.org/10.1007/s11136-008-9399-1
164. Rein DB, Wittenborn JS, Zhang X, Allaire BA, Song MS, Klein R, et al. The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy. Health Serv Res 2011;46:1534-61. http://dx.doi.org/10.1111/j.1475-6773.2011.01263.x
165. Department of Health (DH). NHS Reference Costs 2012 to 2013. London: DH; 2013. URL: www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 (accessed 18 March 2014).
166. Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 2012;96:688-93. http://dx.doi.org/10.1136/ bjophthalmol-2011-300726
167. Meads C, Hyde C, Lafuma A. How much is the cost of visual impairment: caveat emptor. PharmacoEconomics 2006;24:207-10. http://dx.doi.org/10.2165/00019053-200624020-00008
168. Curtis L. Unit Costs of Health and Social Care 2013. Canterbury: PSSRU, University of Kent; 2013. URL: www.pssru.ac.uk/project-pages/unit-costs/2013/ (accessed 18 March 2014).
169. Diabetic Retinopathy Vitrectomy Study Research Group. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report #1. Ophthalmology 1985;92:492-502. http://dx.doi.org/10.1016/ S0161-6420(85)34002-2
170. Office for National Statistics (ONS). UK Interim Life Tables, 1980-82 to 2008-10. 2011. URL: http://www.ons.gov.uk/ons/taxonomy/index.html?nscl = Interim+Life+Tables (accessed 18 April 2014).
171. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia 2006;49:660-6. http://dx.doi.org/10.1007/s00125-005-0120-4
172. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006;23:516-21. http://dx.doi.org/10.1111/j.1464-5491.2006.01838.x
173. Cusick M, Meleth AD, Agrón E, Fisher MR, Reed GF, Knatterud GL, et al. Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27. Diabetes Care 2005;28:617-25. http://dx.doi.org/10.2337/ diacare.28.3.617
174. Klein R, Klein BE, Moss SE, Cruickshanks KJ. Association of ocular disease and mortality in a diabetic population. Arch Ophthalmol 1999;117:1487-95. http://dx.doi.org/10.1001/archopht.117.11.1487
175. Briggs A, Claxton K, Schulpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
176. Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess 2007;11(47). http://dx.doi.org/10.3310/ hta11470
177. Drummond M, McGuire A. Economic Evaluation in HealthCare: Merging Theory with Practice. Oxford: Oxford University Press; 2001.
178. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 65, March 2013. London: BMA and RPS; 2013.
179. National Institute for Health and Clinical Excellence (NICE). Bevacizumab (Avastin) for Eye Conditions. Report of Findings from a Workshop Held at NICE on 13 July 2010. 2010. URL: www.nice.org.uk/ media/AC2/3C/BevacizumabEyeConditionsPrescopingReport.pdf (accessed 25 March 2014).
180. NICE Decision Support Unit. Macular Oedema - Bevacizumab as a Comparator; 2013. URL: www.nicedsu.org.uk/Macular-oedema-bevacizumab(2804604).htm (accessed 25 March 2014).
181. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24. http://dx.doi.org/10.1111/j.1464-5491. 2008.02430.x
182. Malkin AG, Goldstein JE, Perlmutter MS, Massof RW. Responsiveness of the EQ-5D to the effects of low vision rehabilitation. Optom Vis Sci 2013;90:799-805. http://dx.doi.org/10.1097/ OPX.0000000000000005
183. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. URL: http://publications.nice.org.uk/guide-to-the-methods-of-technologyappraisal- 2013-pmg9 (accessed 21 March 2014).
184. Peacock S, Misajon R, Iezzi A, Richardson J, Hawthorne G, Keeffe J. Vision and quality of life: development of methods for the VisQoL vision-related utility instrument. Ophthalmic Epidemiol 2008;15:218-23. http://dx.doi.org/10.1080/09286580801979417
185. Misajon R, Hawthorne G, Richardson J, Barton J, Peacock S, Iezzi A, et al. Vision and quality of life: the development of a utility measure. Invest Ophthalmol Vis Sci 2005;46:4007-15. http://dx.doi.org/10.1167/iovs.04-1389
186. Dewan V, Lambert D, Edler J, Kymes S, Apte RS. Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2012;119:1679-84. http://dx.doi.org/10.1016/j.ophtha.2012.01.049
187. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med 2014;160:18-29. http://dx.doi.org/10.7326/M13-0768
188. Estudillo M, Gonzalez V. Proliferative Diabetic Retinopathy. A comparison of anti-VGEF therapy and laser in preserving visual function in patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2013;54:5760.
189. Gonzalez V. The impact on vision and regression of retinal neovascularization of anti-VEGF induction in combination with quarterly anti-VEGF maintenance or selective PRP versus standard PRP. Invest Ophthalmol Vis Sci 2013;54:4599.
190. Leal S, Figueira J, Ribeiro L, Cachulo ML, Silva R, Nunes S, et al. Combination of intravitreal injection of Pegaptanib plus progressive PRP versus full PRP alone in patients with High Risk Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci 2013;54:2439.
191. Madeira MIA, Neves J, Abdala M. A different approach of pan retinal photocoagulation for the treatment of proliferative diabetic retinopathy (external ring photocoagulation). Paper presented at the IX Euretina Congress, Nice, May 2009.
192. Preti R, Mutti A, Vazquez L, Ferraz D, Zacharias L, Carra M, et al. Evaluation of choroidal thickness in high-risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a 3 months, randomized, controlled and masked clinical trial. Invest Ophthalmol Vis Sci 2013;54:2447.
193. Preti RC, Ramirez LM, Barros AC, Motta AA, Morita C, Maia Junior OO, et al. Structural and functional macular evaluation in proliferative diabetic retinopathy patients treated using panretinal photocoagulation combined with intravitreal bevacizumab injections. Invest Ophthalmol Vis Sci 2012;53:357.
194. Lohmann C, Voegeler J, Liakopoulos S, Wiedemann P, Spital G, Lang G, et al. Double-masked trial demonstrates superiority of combined ranibizumab plus laser versus laser in patients with diabetic macular edema with or without proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2013;54:1239.
195. Ehrlich J, Domalpally A, Yau L, Hopkins J, Ip M. Effects of intravitreal ranibizumab on diabetic retinopathy severity: 36 month data from the RISE and RIDE phase III trials. Invest Ophthalmol Vis Sci 2013;54:4028.
196. Miller DG, Diabetic Retinopathy Clinical Research Network. Exploratory analysis of diabetic retinopathy worsening (progression) at 1 year and 3 years in a randomized clinical trial evaluating ranibizumab and triamcinolone. Invest Ophthalmol Vis Sci 2012;53:366.
197. Ferraz D, Sophie R, Bittencourt M, Preti R, Vazquez L, Motta A, et al. Intravitreal ranibizumab combined with panretinal photocoagulation in patients with treatment-naive proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2013;54:5761.
198. Medical Research Council NIHR. Efficacy and Mechanism Evaluation Programming EME Board: decisions from meeting, London, February 2013. URL: www.nets.nihr.ac.uk/__data/assets/pdf_file/ 0008/66995/outcomes-feb-2013.pdf (accessed 12 March 2014).
199. Centre for Health Economics and Medicines Evaluation. 2013/14 Winter Newsletter of the Centre for Health Economics and Medicines Evaluation (CHEME). 2014. URL: http://cheme.bangor.ac.uk/ documents/2013_14%20Winter%20Newsletter%20CHEME.pdf (accessed 25 March 2014).
200. Davis BM, Normando EM, Guo L, O'Shea P, Moss SE, Somavarapu S, et al. Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes. Small 2014;10:1575-84. http://dx.doi.org/10.1002/smll.201303433
201. National Institute for Health Research (NIHR). SR-13/101/47: Laser Photocoagulation for Non-Proliferative Diabetic Retinopathy; 2013. URL: www.nets.nihr.ac.uk/projects/sr/1310147 (accessed 25 March 2014).
202. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 1991;98:786-806. http://dx.doi.org/10.1016/ S0161-6420(13)38012-9